StockMacro
Menu

IRulya Therapeutics

$39.88 +23% in 6 monthsMarket cap $432.4M

IRLA on XNAS, Health Care, IRulya Therapeutics Inc., job postings

Measures activity, not value. Not investment advice.

Delisting notice filed and 5 officer or director changes in 90 days, while the stock rose 15% in a month.

  • GoodInstitutional holders rose to 32 from 27 last quarter
  • BadNet loss of $106.8M over 12 months against cash of $105.2M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
38
Website
quincetx.com
Listed
Nasdaq, US
Last results
13 Nov 2026
Next results
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $27.7M.
Quarter to 31 Dec 2021: revenue –, net income -$23.4MQuarter to 31 Mar 2022: revenue –, net income -$21.6MQuarter to 30 Jun 2022: revenue –, net income -$16.6MQuarter to 30 Sep 2022: revenue –, net income -$7.9MQuarter to 31 Dec 2022: revenue –, net income -$5.5MQuarter to 31 Mar 2023: revenue –, net income -$12.3MQuarter to 30 Jun 2023: revenue –, net income -$4.9MQuarter to 30 Sep 2023: revenue –, net income -$5.4MQuarter to 31 Dec 2023: revenue –, net income -$8.9MQuarter to 31 Mar 2024: revenue –, net income -$11.1MQuarter to 30 Jun 2024: revenue –, net income -$27.7MQuarter to 30 Sep 2024: revenue –, net income -$5.5MQuarter to 31 Dec 2024: revenue –, net income -$12.5MQuarter to 31 Mar 2025: revenue –, net income -$15.0MQuarter to 30 Jun 2025: revenue –, net income -$16.0MQuarter to 30 Sep 2025: revenue –, net income -$13.4MQuarter to 31 Dec 2025: revenue –, net income -$39.5MQuarter to 31 Mar 2026: revenue –, net income $35.9MQuarter to 30 Jun 2026: revenue –, net income -$75.5MQuarter to 30 Sep 2026: revenue –, net income -$27.7M
31 Dec 2021RevenueNet incomeNet losstallest bar $75.5M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$27.7M
30 Jun 2026–-$75.5M
31 Mar 2026–$35.9M
31 Dec 2025–-$39.5M
30 Sep 2025–-$13.4M
30 Jun 2025–-$16.0M
31 Mar 2025–-$15.0M
31 Dec 2024–-$12.5M
30 Sep 2024–-$5.5M
30 Jun 2024–-$27.7M
31 Mar 2024–-$11.1M
31 Dec 2023–-$8.9M
30 Sep 2023–-$5.4M
30 Jun 2023–-$4.9M
31 Mar 2023–-$12.3M
31 Dec 2022–-$5.5M
30 Sep 2022–-$7.9M
30 Jun 2022–-$16.6M
31 Mar 2022–-$21.6M
31 Dec 2021–-$23.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$106.8M -$57.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$12.50 -$122.28
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$39.0M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $105.2M $26.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $17.5M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – -$8.8M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
IRulya TherapeuticsIRLA (this company) $432.4Mloss–––
Tectonic TherapeuticTECX $405.3Mloss–––
TevogenTVGN $405.2Mloss–––
Fennec PharmaceuticalsFENC $462.1M2287.0+71%3.1%
Candel TherapeuticsCADL $395.4Mloss–––
RegenxbioRGNX $473.4Mloss3.1-4.6%-114%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+19%

32 13F filers vs 27

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

21%

2.2M shares held by 13F filers (30 Sep 2026) of 10.8M outstanding (5 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.2%

128K shares sold short (30 Oct 2026) of 10.8M outstanding (5 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.1

128K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-17%

155K shares sold short in the report before, 128K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

62%

62% of off-exchange volume on 20 Nov 2026 was short sales

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

11 articles in the last 7 days; its usual week has 1.

Price $39.88 on 20 Nov 2026, +23% over 12 months (12-month range $27.87 to $40.59)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $174K in the last 12 months (the 12 months before: $0).
Capital spending per quarter. Capital spending $71K in the latest quarter, -4.1% on a year earlier.
Institutional holders (13F filers). 32 13F filers reported holding it in the latest 13F quarter, -27% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
9 Oct 20268-K and other filingsDirector or officer change
6 Oct 20268-K and other filingsDirector or officer change
2 Oct 20268-K and other filingsDirector or officer change
14 Sep 20268-K and other filingsDirector or officer change
14 Sep 20268-K and other filingsCompleted an acquisition or asset sale
4 Sep 20268-K and other filingsDelisting notice or listing transfer
27 Aug 20268-K and other filingsDirector or officer change
31 Jul 20268-K and other filingsDirector or officer change
11 Jun 20268-K and other filingsPrivate placement of securities (Form D)
11 Jun 20268-K and other filingsPrivate placement of securities (Form D)
18 May 20268-K and other filingsDirector or officer change
18 May 20268-K and other filingsCompleted an acquisition or asset sale
22 Apr 20268-K and other filingsDirector or officer change
1 Apr 20268-K and other filingsReport will be filed late
30 Mar 20268-K and other filingsA major agreement ended
20 Mar 20268-K and other filingsDelisting notice or listing transfer
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 24 vs usual 6 (2025-12-31); 4.8x the same period a year earlier
2 Feb 20268-K and other filingsDirector or officer change
2 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Jul 20258-K and other filingsPrivate placement of securities (Form D)
4 Sep 2024Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 163K)
21 Jun 20248-K and other filingsDelisting notice or listing transfer
15 Feb 20248-K and other filingsDirector or officer change
29 Jan 20248-K and other filingsDirector or officer change
29 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Dec 20238-K and other filingsA major agreement ended
8 Dec 20238-K and other filingsDelisting notice or listing transfer
26 Oct 20238-K and other filingsDirector or officer change
23 Oct 20238-K and other filingsDirector or officer change
23 Oct 20238-K and other filingsCompleted an acquisition or asset sale
6 Sep 20238-K and other filingsDirector or officer change
10 Aug 20238-K and other filingsDirector or officer change
10 Aug 2023Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 197K)
24 Jul 20238-K and other filingsDirector or officer change
24 Jul 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Mar 20238-K and other filingsDirector or officer change
3 Mar 20238-K and other filingsDirector or officer change
30 Jan 20238-K and other filingsRestructuring costs announced
27 Jan 20238-K and other filingsDirector or officer change
27 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Dec 20228-K and other filingsDelisting notice or listing transfer
30 Sep 20228-K and other filingsDirector or officer change
22 Jul 20228-K and other filingsDirector or officer change
10 Jun 20228-K and other filingsDirector or officer change
20 May 20228-K and other filingsDirector or officer change
20 May 20228-K and other filingsCompleted an acquisition or asset sale
12 May 20228-K and other filingsDirector or officer change
2 May 20228-K and other filingsDirector or officer change
2 May 20228-K and other filingsRestructuring costs announced
15 Mar 20228-K and other filingsDirector or officer change
2 Feb 20228-K and other filingsDirector or officer change
2 Feb 20228-K and other filingsRestructuring costs announced
2 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Jun 2022: -$31K published
Month from 1 Mar 2023: -$2K published
Month from 1 Aug 2023: $633K published
Month from 1 Sep 2023: $108K published
Month from 1 Dec 2023: $168K published
Month from 1 Aug 2024: $56K published
Month from 1 Sep 2024: $107K published
Month from 1 Dec 2025: -$174K published
Capital spending per quarter
Quarter ended 31 Dec 2021: $44K, +340% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $5K, -86% on a year earlier; public on 11 May 2022
Quarter ended 30 Sep 2022: $50K; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $78K, +77% on a year earlier; public on 16 Mar 2023
Quarter ended 31 Mar 2023: $136K, +2620% on a year earlier; public on 16 May 2023
Quarter ended 31 Dec 2023: $24K, -69% on a year earlier; public on 2 Apr 2024
Quarter ended 31 Mar 2024: $39K, -71% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $39K; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $46K; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $133K, +454% on a year earlier; public on 25 Mar 2025
Quarter ended 31 Mar 2025: $148K, +279% on a year earlier; public on 14 May 2025
Quarter ended 30 Jun 2025: $126K, +223% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $74K, +61% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 12 May 2026
Quarter ended 30 Sep 2026: $71K, -4.1% on a year earlier; public on 14 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 92; public on 14 Feb 2022
31 Mar 2022 report: 83; public on 16 May 2022
30 Jun 2022 report: 67; public on 15 Aug 2022
30 Sep 2022 report: 56; public on 14 Nov 2022
31 Dec 2022 report: 48; public on 14 Feb 2023
31 Mar 2023 report: 38; public on 15 May 2023
30 Jun 2023 report: 35; public on 14 Aug 2023
30 Sep 2023 report: 34; public on 14 Nov 2023
31 Dec 2023 report: 40; public on 14 Feb 2024
31 Mar 2024 report: 43; public on 15 May 2024
30 Jun 2024 report: 41; public on 14 Aug 2024
30 Sep 2024 report: 29; public on 14 Nov 2024
31 Dec 2024 report: 33; public on 14 Feb 2025
31 Mar 2025 report: 36; public on 15 May 2025
30 Jun 2025 report: 40; public on 14 Aug 2025
30 Sep 2025 report: 44; public on 14 Nov 2025
31 Dec 2025 report: 66; public on 17 Feb 2026
31 Mar 2026 report: 44; public on 15 May 2026
30 Jun 2026 report: 27; public on 14 Aug 2026
30 Sep 2026 report: 32; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $174K (29 Dec 2025), higher than 73% of its own history.
  • Insider net buying (open market): Insiders sold a net $174K in the last 12 months (the 12 months before: $0).
  • Capital spending per quarter: Capital spending $71K in the latest quarter, -4.1% on a year earlier.
  • Institutional holders (13F filers): 32 13F filers reported holding it in the latest 13F quarter, -27% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 45 insider trades

No trades in the last 90 days; the latest was filed 29 Dec 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
29 Dec 2025Luca BenattiDirectorSell50,000$3.47$174KForm 4
3 Sep 2024Dirk ThyeCEO AND CHIEF MEDICAL OFFICERBuy154,500$0.69$107KForm 4
22 Aug 2024Charles S. RyanPRESIDENTBuy48,387$0.65$31KForm 4
21 Aug 2024Brendan HannahCHIEF BUSINESS OFFICER AND COOBuy38,924$0.62$24KForm 4
14 Dec 2023David LamondDirectorBuy67,881$1.02$69KForm 4
7 Dec 2023David LamondDirectorBuy57,369$1.01$58KForm 4
1 Dec 2023David LamondDirectorBuy43,134$0.94$41KForm 4
31 Aug 2023David LamondDirectorBuy82,052$1.31$108KForm 4

32 institutions reported shares at the end of Q3 2026, 21% of the shares outstanding; 8 opened a position, 5 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Janus Henderson Group Ltd.1.7M15.8%$53.2M
Ikarian Capital, LLC96K0.88%$3.0M+23K+32%
Squadron Capital Management LLC90K0.83%$2.8M+50K+123%
Millennium Management LLC72K0.67%$2.2M+1,475+2.1%
Balyasny Asset Management L.P.70K0.65%$23.5M+30%
Acuta Capital Partners, LLC53K0.49%$1.6MNew+53K
Birchview Capital, LP41K0.37%$1.3MNew+41K
Boothbay Fund Management, LLC21K0.20%$660K+7,380+53%
Jane Street Group, LLC20K0.19%$625K+7,514+59%
Seven Fleet Capital Management LP12K0.11%$372KNew+12K

Company events

All 69 company events

In 12 months: 9 director or officer changes, 2 delisting notices, 2 completed deals, 2 private placements. Results releases and routine reports are left out.

FiledWhat happenedSource
9 Oct 2026Director or officer changeSame filing: changed its bylaws or fiscal year8-K
6 Oct 2026Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K
2 Oct 2026Director or officer change8-K
14 Sep 2026Director or officer change; Completed an acquisition or asset sale8-K
4 Sep 2026Delisting notice or listing transfer8-K
27 Aug 2026Director or officer change8-K
31 Jul 2026Director or officer change8-K
11 Jun 2026Private placement of securities (Form D)$114.7M sold of $186.4M offeredD

The 5 newest of 74 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 9 Oct 2026Filings record

    Director or officer change

  2. 6 Oct 2026Filings record

    Director or officer change

  3. 2 Oct 2026Filings record

    Director or officer change

  4. 14 Sep 2026Filings record

    Director or officer change

  5. 14 Sep 2026Filings record

    Completed an acquisition or asset sale

  6. 4 Sep 2026Filings record

    Delisting notice or listing transfer

  7. 27 Aug 2026Filings record

    Director or officer change

  8. 31 Jul 2026Filings record

    Director or officer change

  9. 11 Jun 2026Filings record

    Private placement of securities (Form D)

  10. 11 Jun 2026Filings record

    Private placement of securities (Form D)

  11. 18 May 2026Filings record

    Director or officer change

  12. 18 May 2026Filings record

    Completed an acquisition or asset sale

  13. 22 Apr 2026Filings record

    Director or officer change

  14. 1 Apr 2026Filings record

    Report will be filed late

  15. 30 Mar 2026Filings record

    A major agreement ended

  16. 20 Mar 2026Filings record

    Delisting notice or listing transfer

  17. 17 Feb 2026Institutional holdings change

    saw 24 13F filers open a new position in the quarter ended 31 Dec 2025, 4.8× the same quarter last year.

    Same quarter last year: 5; its normal quarter is 6.

    See the evidence
    This period
    24 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    6
    Typical spread (median absolute deviation)
    1
    How far from its usual level
    +6.0
    Same quarter last year
    5
    History used
    2,376 days
    2023-12-31: 62024-03-31: 62024-06-30: 22024-09-30: 12024-12-31: 52025-03-31: 72025-06-30: 102025-09-30: 62025-12-31: 24
    the quarter ended 31 Dec 20258 earlier quartersnormal: 6

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  18. 2 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 2 Feb 2026Filings record

    Director or officer change

  20. 1 Jul 2025Filings record

    Private placement of securities (Form D)

  21. 4 Sep 2024Insiders change

    had 3 insiders buy $163K of its shares on the open market within 30 days (3 filings).

    Who bought: Hannah Brendan, Ryan Charles S., Thye Dirk.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $163K
    Window
    5 Aug 2024 to 4 Sep 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  22. 4 Sep 2024Insiders record

    Thye Dirk (CEO AND CHIEF MEDICAL OFFICER) bought 154,500 shares of QNCX ($107,375) (dated 3 Sep 2024)

  23. 23 Aug 2024Insiders record

    Ryan Charles S. (PRESIDENT) bought 48,387 shares of QNCX ($31,452) (dated 22 Aug 2024)

  24. 22 Aug 2024Insiders record

    Hannah Brendan (CHIEF BUSINESS OFFICER AND COO) bought 38,924 shares of QNCX ($24,166) (dated 21 Aug 2024)

  25. 21 Jun 2024Filings record

    Delisting notice or listing transfer

  26. 15 Feb 2024Filings record

    Director or officer change

  27. 29 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 29 Jan 2024Filings record

    Director or officer change

  29. 22 Dec 2023Filings record

    A major agreement ended

  30. 15 Dec 2023Insiders record

    Lamond David (director) bought 67,881 shares of QNCX ($69,233) (dated 14 Dec 2023)

  31. 8 Dec 2023Filings record

    Delisting notice or listing transfer

  32. 8 Dec 2023Insiders record

    Lamond David (director) bought 57,369 shares of QNCX ($58,134) (dated 7 Dec 2023)

  33. 2 Dec 2023Insiders record

    Lamond David (director) bought 43,134 shares of QNCX ($40,546) (dated 1 Dec 2023)

  34. 26 Oct 2023Filings record

    Director or officer change

  35. 23 Oct 2023Filings record

    Director or officer change

  36. 23 Oct 2023Filings record

    Completed an acquisition or asset sale

  37. 6 Sep 2023Filings record

    Director or officer change

  38. 1 Sep 2023Insiders record

    Lamond David (director) bought 82,052 shares of QNCX ($107,898) (dated 31 Aug 2023)

  39. 18 Aug 2023Insiders record

    Lamond David (director) bought 250,000 shares of QNCX ($325,737) (dated 17 Aug 2023)

  40. 12 Aug 2023Insiders record

    Thye Dirk (Chief Executive Officer) bought 88,000 shares of QNCX ($110,880) (dated 11 Aug 2023)

Showing the newest 40 of 97 entries; narrow the window or the kind of data to see older ones.

Not listed: 98 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001662774
Ticker
IRLA
Domain
quincetx.com
Hq location
CT|NEW HAVEN|06510 (1 unverified)
Name
Cortexyme, Inc., IRulya Therapeutics Inc., Quince Therapeutics, Inc.
  • SEC Form 13F institutional holdings270 data points30 Jun 2019 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)138 records5 Jan 2016 to 13 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)502 data points31 Dec 2017 to 5 Nov 2026
  • SEC Form 4 insider transactions45 records, 148 data points14 May 2019 to 29 Dec 2025
  • FINRA short interest (twice monthly)6 data points15 Oct 2026 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)60 data points12 Oct 2026 to 20 Nov 2026